All News
Efficacy and safety of deucravacitinib up to week 52 in the POETYK PsA-2 study
•ACR20 at W16: 54.2% (deucravacitinib) vs 39.4% (placebo), p=0.0002
•PASI75: 40.9% vs 15.4%, p<0.0001
•MDA: 25.6% vs 14.7%, p=0.0007
•FACIT-F: +2.5 vs +1.8
•SAE: 1.9% (low)
TYK2 inhibition shows https://t.co/JXTZRk2itA
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
❓️Is early intensive therapy with combination csDMARDs or TNFi superior to standard step care for the treatment of moderate to severe #psoriatic_arthritis?
🅰️ Yes
🔅Check out the SPEED RCT presented by @DrLauraCoates at #EULAR2025
OP0089
@RheumNow
#Strategy https://t.co/24e7wUV2FB
Nelly ZIADE 🍀 Nellziade ( View Tweet)
#EULAR2025 Abstr#OP0078 #Lupus nephritis is assoc with CVD. Propensity matched analysis comparing GLP-1 agonist vs SLGT2-i using TrinetX database in LN ->favourable risk reduction with GLP-1:
-CKD progression
-Mortality
-MI
Validation & mechanistic explanation needed @RheumNow https://t.co/xPDVDm1CHm
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
In propensity-matched RA cohort (n=2,449 each) on JAK inhibitors, adding a GLP-1 agonist reduced risk of: • Acute coronary syndromes (RR 0.65, p=0.0009) • DVT (RR 0.69, p=0.007) Overall CV events ↓ by 33% (RR 0.67, p=0.0007)
#EULAR2025 @RheumNow
Abstract#OP0069 https://t.co/jWI6tvri8O
Jiha Lee JihaRheum ( View Tweet)
Can RA be intercepted?
In the ALTO follow-up of the APIPPRA RCT (Cope et al), 1 year of abatacept delayed RA onset by up to 3 years in ACPA+/RF+ individuals. Effect strongest in those with mature autoantibody profiles.
Abstract#OP0004
@RheumNow #EULAR2025 https://t.co/N7YwtYod8w
Jiha Lee JihaRheum ( View Tweet)
Repurposing drugs to #osteoarthritis
No jewel in the rough!
Most drugs - MTX, colchicine, TNFi, IL1i, etc are NEGATIVE or yield mixed results from diff #RCTs
Not sure this is the way forward for #OA drug discovery 💡
#EULAR2025 @RheumNow @eular_org
Abst#POS565 https://t.co/A6SdXtOo7v
Janet Pope Janetbirdope ( View Tweet)
RA pts have ↑ risk of DVT (HR 2.26) & PE (HR 1.61) vs controls in this 40-year, pop-based study. Nodules, obesity, high disease activity & early biologic use ↑ risk. Remission in year 1 halved PE risk. VTE risk persists despite therapeutic advances.
@RheumNow #EULAR2025 #OP0070 https://t.co/AaBi2o2cUw
Mrinalini Dey DrMiniDey ( View Tweet)
GI symptoms in axSpA
-Cohort of 370 pts with axSpAfrom New Zealand
-Elevated fecal calprotectin ➡️ positive correlation with GI symptoms and high disease activity
-Bowel symptoms associated with reduced quality of life.
-Use of TNFi improved bowel symptoms over time. https://t.co/wA37G3HWyi
Links:
Adela Castro AdelaCastro222 ( View Tweet)
IL-17 inhibition for PMR? In the secukinumab ph2 in GCA (TitAIN), patients with PMR did really well, seemingly outperforming steroid taper in the placebo arm. Real promise, will be great to see how the ph3 in PMR (REPLENISH) goes OP0062 #EULAR2025 @RheumNow https://t.co/cisA0GiUx1
David Liew drdavidliew ( View Tweet)
MONITOR PsA 200+ pts secondary care "real-life" cohort
65 treated w/ combi csDMARDs
48weeks outcome and 96 weeks
49% bioDMARDs, 29% retention and 23% deescalation to 1 csDMARD
‼️reasons for discontinuation was AEs in 60% cases not inefficacy
Caveat: analysis not adjusted for https://t.co/L8EczgZTpP
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
A PT-led vocational intervention for RA/axSpA with reduced work ability was likely cost-effective: ↓€4,324 in societal costs & +0.05 QALYs over 12m vs usual care (95% probability at €20k/QALY). Results suggest cost-effective compared to usual care.
@RheumNow #EULAR2025 #OP0007
Mrinalini Dey DrMiniDey ( View Tweet)
RA polygenic risk ≠ MI risk. In >8,700 Swedes w/ or w/o RA, higher genetic risk for RA wasn’t linked to higher MI incidence. Familial clustering of RA & MI likely driven by non-genetic factors. Traditional CV risk still key in RA care.
@RheumNow #EULAR2025 #OP0072 https://t.co/KN6Dg0ekt2
Mrinalini Dey DrMiniDey ( View Tweet)
Xeligekimab in AS:
-IL-17A blocker
-Phase 3 study on Chinese pts showed sustained efficacy until week 48.
-Significant improvement on DAI measures as well.
-Fully humanized IgG4 mab may last longer in system and possible less ADAs.
Abstract #OP0102 #EULAR2025 @RheumNow https://t.co/vyNHZ9ssFt
Links:
Adela Castro AdelaCastro222 ( View Tweet)
📊 POS0574 @rheumnow #EULAR2025 Real-world data from SERENA shows sustained 5-year effectiveness of secukinumab in PsA. ✔️ 57% had no tender/swollen joints at Year 5 ✔️ PASI90 in ~48% ✔️ Stable low TJC, SJC & PtGA Durability confirmed even in prior biologic users. https://t.co/eNpboTRRu3
Jiha Lee JihaRheum ( View Tweet)
Clinical determinants of multiple drug failure in D2T RA
2000+ RA cohort 250+ refractory
-Low financial status
-Cancer Hx
-CV comorbidities
-Chronic use of NSAID or GCs
Protective: Regular participation in leisure activities
#POS0030 @RheumNow #EULAR2025 https://t.co/qNHQoHCb80
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
REGULATE-RA and REGULATE-HS FIH CAR-Treg targeting Cit-P
Refractory RA (at least 3 MoA)
3 RA pts dosed & 3 Hidradenitis Suppurativa 0 SAE, DLTs or CRS
Grade 1 TEAs mainly, one Grade 2
Efficacy and PD analysis ongoing
#POS0034 #EULAR2025 @RheumNow https://t.co/Glw3NNFepF
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
If you successfully taper off DMARDs in RA patients in remission, do you risk bringing new joints in the mix?
Leiden post-hoc trial: these patients don’t do worse than those who never get off drug.
Drug-free remission tricky but new joints not a worry. #EULAR2025 @RheumNow https://t.co/QDxNRPN9f1
David Liew drdavidliew ( View Tweet)
In >228k CTD patients across France, ILD increased mortality risk across all CTDs. Proportion of incident CTD with ILD highest in IIM (37%). Up to 34% of CTD-ILD pts had progressive pulm fibrosis. Supports earlier ILD screening & vigilance in CTDs.
@RheumNow #EULAR2025 #OP0033 https://t.co/KkF9xFY4Cn
Mrinalini Dey DrMiniDey ( View Tweet)
First line TNFi in RA in 140+ pts vs Standard of Care
At 5 yrs outcome
OR drug free remission 2.2
But no longer significant at 10yrs
OR sustained remission 10yrs 1.91
OR single bioDMARDs 10yrs 2.64
Less 1% D2T
#Poster0027 #EULAR2025 @RheumNow https://t.co/sL2XCbxPbl
Aurelie Najm AurelieRheumo ( View Tweet)
Access inequity across Europe is real.
New #RheumaFacts data show major gaps in RMD care:
🔹 Full tsDMARD access in just 4% of countries
🔹 Self-referral possible in 57%
🔹 Rheum physio reimbursed in 63%
🔹 Psych care? Only 30%.
Abstract#OP0025
@RheumNow #EULAR2025
Jiha Lee JihaRheum ( View Tweet)
